KyungdongPharm
Financials
Valuation Metrics
KyungdongPharm's Market Cap is ₩1514B. At end of 2025 it was ₩1797B. Ranked #960 of 2,405 in KR market (top 40%), #467 of 1,627 on KOSDAQ (top 29%), #113 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 49%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 151.38B KRW | KR#960/2,405 Sec#113/231 |
| Revenue | 201.12B KRW | KR#1,034/2,405 Sec#61/231 |
| Net Income | 17.73B KRW | KR#750/2,405 Sec#49/231 |
| Total Assets | 307.84B KRW | KR#1,019/2,405 Sec#67/231 |
| Net Assets | 231.58B KRW | KR#863/2,405 Sec#59/231 |
| Employees | 383 | KR#637/2,405 Sec#55/231 |
| Value | ||
| P/E | 8.54x | KR#757/2,405 Sec#39/231 |
| P/B | 0.65x | KR#1,123/2,405 Sec#62/231 |
| PEG | 0.01x | KR#79/2,405 Sec#4/231 |
| P/S | 0.75x | KR#1,238/2,405 Sec#66/231 |
| EV/EBITDA | 13.90x | KR#857/2,405 Sec#49/231 |
| FCF Yield | -0.96% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 7.66% | KR#824/2,405 Sec#58/231 |
| ROA | 5.76% | KR#651/2,405 Sec#53/231 |
| Op. Margin | 5.85% | KR#853/2,405 Sec#64/231 |
| Revenue Growth | 3.46% | KR#1,287/2,405 Sec#131/231 |
| Earnings Growth | 1550.53% | KR#46/2,405 Sec#4/231 |
| Financial Health | ||
| Debt Ratio | 32.93% | KR#644/2,405 Sec#75/231 |
| Total Debt | 25.40B KRW | KR#1,292/2,405 Sec#101/231 |
| FCF | -1.46B KRW | KR#1,301/2,405 Sec#102/231 |
| Cash | 13.14B KRW | KR#1,524/2,405 Sec#123/231 |
| Current Ratio | 1.77x | KR#989/2,405 Sec#110/231 |
| Net Debt/EBITDA | 1.04x | KR#738/2,405 Sec#49/231 |
| Dividend | ||
| Div. Yield | 6.07% | KR#205/2,405 Sec#5/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -13.38% | KR#954/2,405 Sec#59/231 |
| 1M Return | -1.99% | KR#456/2,405 Sec#46/231 |
| From 52W High | -21.53% | KR#220/2,405 Sec#13/231 |
| 1Y MDD | -23.38% | KR#108/2,405 Sec#6/231 |
| Trading | ||
| Volume | 12,552 shares | KR#1,742/2,405 Sec#170/231 |
| Trading Value | 61.7M KRW | KR#1,625/2,405 Sec#167/231 |
| Foreign Own. | 1.98% | KR#1,628/2,405 Sec#159/231 |
| Per Share | ||
| EPS | 576 KRW | KR#942/2,405 Sec#66/231 |
| BPS | 7,527 KRW | KR#1,184/2,405 Sec#88/231 |
Company Info
Kyungdong Pharm, established in 1976, manufactures and sells pharmaceuticals, specializing in professional medications like circulatory and digestive system agents, and antihypertensive drugs, including products such as Duoroban Tablets and Alfortin Soft Capsules. The company boasts state-of-the-art solid formulation and injectable manufacturing facilities that meet EU-GMP and US c-GMP standards. Leveraging proprietary raw material synthesis and formulation technologies, it achieves continuous revenue growth through combination drug development, increased investment in biotech firms, and the launch of its WIAVIM health functional food brand.